ERNA Eterna Therapeutics Inc

Price (delayed)

$3.93

Market cap

$4.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$25.9

Enterprise value

-$4.2M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 11
Highlights
ERNA's equity has surged by 186% since the previous quarter
Eterna Therapeutics's EPS has soared by 97% YoY and by 54% from the previous quarter
ERNA's gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY

Key stats

What are the main financial stats of ERNA

ERNA stock price

How has the Eterna Therapeutics stock price performed over time
Intraday
-1.5%
1 week
-38.79%
1 month
-37.62%
1 year
-92.51%
YTD
-86.9%
QTD
-40.9%

Financial performance

How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.09M
Net income
-$11.39M
Gross margin
N/A
Net margin
N/A
ERNA's gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
Eterna Therapeutics's net income has soared by 75% YoY and by 19% from the previous quarter
The operating income fell by 33% QoQ but it rose by 14% YoY

Price vs fundamentals

How does ERNA's price correlate with its fundamentals

Growth

What is Eterna Therapeutics's growth rate over time

Valuation

What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eterna Therapeutics's EPS has soared by 97% YoY and by 54% from the previous quarter
ERNA's equity has surged by 186% since the previous quarter
ERNA's P/B is 70% below its last 4 quarters average of 2.2
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Eterna Therapeutics business performance
ERNA's return on equity has surged by 79% since the previous quarter
The ROA has grown by 47% YoY and by 34% from the previous quarter

Dividends

What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ERNA.

Financial health

How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 186% higher than its total liabilities
Eterna Therapeutics's current ratio has surged by 186% QoQ
Eterna Therapeutics's total assets has surged by 108% YoY and by 81% QoQ
The debt is 94% lower than the equity
ERNA's equity has surged by 186% since the previous quarter
The debt to equity has soared by 113% YoY but it has plunged by 70% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.